Free tool
Rare disease stocks
We cover 18 companies grouped under the Rare disease theme. The median market value in the group is $264.31M. Across the group, the median move over the past trading day is +0.20%. Price change over the past year runs from +18.3% to +629.5% across the middle 80 percent of the group, with a median of +131.3%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
18 of 268 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| ETON | Eton Pharmaceuticals, Inc. | $62.62 | +34.20% | +285.12% | +262.38% |
| FBRX | Forte Biosciences, Inc. | $76.99 | +0.44% | +226.09% | +589.87% |
| KALV | KalVista Pharmaceuticals Inc | $27.00 | 0.00% | +74.64% | +98.68% |
| OMER | Omeros Corporation | $18.22 | +61.52% | +11.23% | +328.71% |
| 0QNA.L | Basilea Pharmaceutica AG | 65.80 CHF | +2.73% | +20.16% | +41.96% |
| ASMB | Assembly Biosciences, Inc. | $35.42 | +38.52% | +4.95% | +36.81% |
| AQST | Aquestive Therapeutics, Inc. | $5.39 | +43.35% | −16.43% | +40.00% |
| 0KBU.L | Omeros Corporation | $18.44 | −4.75% | +11.14% | +332.86% |
| 0OB3.L | Valneva SE | 2.87 EUR | +0.75% | −23.95% | −25.05% |
| XUP.DE | Genfit S.A. | 14.08 EUR | −1.81% | +164.41% | +166.82% |
| CRDL | Cardiol Therapeutics Inc. | $2.14 | +78.33% | +115.29% | +91.07% |
| CRDL.TO | Cardiol Therapeutics Inc. | 2.97 CAD | +74.71% | +118.38% | +90.38% |
| SPRB | Spruce Biosciences, Inc. | $61.48 | +47.79% | −32.22% | +721.93% |
| CPIX | Cumberland Pharmaceuticals Inc. | $8.97 | +69.86% | +125.38% | +163.82% |
| 0IIM.L | Esperion Therapeutics, Inc. | $3.19 | +0.14% | −14.28% | +44.65% |
| VYNE | VYNE Therapeutics Inc | $28.56 | +3080.40% | +4824.14% | +8660.74% |
| CMMB | Chemomab Therapeutics Ltd. | $2.59 | +81.12% | +44.69% | −25.57% |
| GLMD | Galmed Pharmaceuticals Ltd. | $4.33 | +710.86% | +426.12% | +211.51% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.